Literature DB >> 8019927

Soft tissue sarcomas in adults.

C P Karakousis1, R P Perez.   

Abstract

Soft tissue sarcomas are relatively rare in adults, accounting for less than one percent of newly diagnosed cancers in the United States each year. However, increased physician awareness of these tumors may lead to earlier diagnosis and improved results. The five-year survival rate has been increasing, and treatment using a combination of modalities has significantly reduced the number of amputations performed. This article reviews the clinical presentation, diagnosis, pathology, and treatment of soft tissue sarcomas in adults.

Entities:  

Mesh:

Year:  1994        PMID: 8019927     DOI: 10.3322/canjclin.44.4.200

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  4 in total

1.  CREPT expression correlates with poor prognosis in patients with retroperitoneal leiomyosarcoma.

Authors:  Yaoguang She; Jiao Liang; Lin Chen; Ying Qiu; Na Liu; Xudong Zhao; Xiaohui Huang; Yinyin Wang; Fangli Ren; Zhijie Chang; Peiyu Li
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  Establishment of a primary human sarcoma model in athymic nude mice.

Authors:  Lars Steinstraesser; Frank Jacobsen; Cornelius Schubert; Kai Gevers; Ingo Stricker; Hans-Ulrich Steinau; Sammy Al-Benna
Journal:  Hum Cell       Date:  2010-05       Impact factor: 4.174

3.  The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era.

Authors:  Ren-Shu Zhang; Jie Liu; Yao-Tiao Deng; Xin Wu; Yu Jiang
Journal:  Cancer Med       Date:  2022-02-22       Impact factor: 4.711

4.  Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas.

Authors:  Sven-T Liffers; Daniel J Tilkorn; Ingo Stricker; Christoph Günter Junge; Sammy Al-Benna; Markus Vogt; Berlinda Verdoodt; Hans-U Steinau; Andrea Tannapfel; Iris Tischoff; Alireza Mirmohammadsadegh
Journal:  BMC Cancer       Date:  2013-10-21       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.